Deanne’s Story

Diagnosis of Gastrointestinal Stromal Tumor (GIST)

In November 2003, during emergency surgery to address persistent vomiting, Deanne underwent resection of a 4.2 cm tumor along with 18 inches of her small intestine. Further testing confirmed a diagnosis of gastrointestinal stromal tumor (GIST), a rare and aggressive cancer type that typically does not respond to chemotherapy or radiation. Although the surgeon removed all visible signs of the tumor, GIST is known for its high recurrence rate. Due to the tumor’s high mitotic index, Deanne was given a poor prognosis.

Clinical Trial Consideration and Treatment Dilemmas

Following her surgery, Deanne’s case was reviewed by a local tumor board. She was referred to the only local oncologist with prior experience managing GIST and was encouraged to join a clinical trial at UC Davis. The trial was designed to test the effectiveness of Gleevec, a targeted therapy, in extending disease-free periods for patients with no current evidence of cancer.

Despite persuasive arguments from the trial physician, Deanne ultimately declined participation. Potential side effects, travel limitations, insurance concerns, and uncertainty about the long-term efficacy of Gleevec influenced her decision. She hoped to preserve this option for potential future use if the disease returned.

Turning to Nontoxic Alternatives

While searching for additional options, Deanne was introduced—through a family connection—to a researcher who had developed protocols for other conditions. He designed a plan for her based on similar cancers. Deanne began the protocol and continued it for over a year without experiencing side effects. During that time, her test results consistently indicated no evidence of disease (NED). She maintained regular monitoring through blood tests and CT scans every three to four months.

Protocol Adherence and Lifestyle Commitment

Deanne followed the recommended protocol with notable consistency. The treatment, which included a compound called “YUCKKO,” was taken once daily in a low dose. As a small-framed individual, this dosage appeared sufficient. Her commitment extended beyond supplements to include dietary discipline, which she maintained even during vacations and special occasions. This level of adherence was considered a key factor in her outcome.

Role of Post-Surgical Supportive Therapy

Surgical removal of visible tumors is rarely curative, as microscopic cancer cells may remain undetected. In place of standard follow-up treatments like chemotherapy and radiation, Deanne’s protocol was used to support recovery and inhibit recurrence. For cases where immediate post-surgical application of such protocols is not possible, a combination with low-dose chemotherapy may be considered. Certain protocol components—such as the polyphenol EGCG—may enhance chemotherapy by inhibiting the development of drug resistance.

Outcome and Long-Term Outlook

Deanne’s original prognosis suggested a life expectancy of five years. However, her health outcomes defied this expectation. More than 16 months after her diagnosis and treatment, she remained free of disease. Her case continues to offer a hopeful example of what may be possible with disciplined follow-through and individualized approaches to care.